Agilent Technologies Inc delivered a solid Q3 2025 (calendar Q3) performance, with revenue of $1.738 billion, up 10.1% year-over-year and 4.2% quarter-over-quarter. The company posted a gross profit of $914 million and a gross margin of 52.6%, producing an operating income of $360 million and an operating margin of 20.7%. Net income reached $336 million, translating to a net margin of 19.3% and earnings per diluted share of $1.18. EBITDA stood at $137 million, reflecting a lean operating expense structure relative to revenue. Free cash flow (FCF) was reported at $573 million, supported by a positive operating cash flow of $362 million and a cash balance of approximately $1.54 billion at period-end. Net debt stood at about $1.87 billion against total liquidity, underscoring a healthy balance sheet and strong cash generation that provides optionality for deleveraging, buybacks, and continued R&D investment.
The quarterly results were driven by a favorable revenue mix and disciplined cost management. R&D spend was $111 million in the quarter, contributing to ongoing innovation in Life Sciences and Diagnostics/Genomics while SG&A was $431 million, yielding a robust operating margin. The company maintained a balance sheet with current assets of $4.25 billion and current liabilities of $1.89 billion, yielding a healthy current ratio (~2.25) and a quick ratio well above risk thresholds. Management commentary (where available) was not included in the provided transcript data; thus, the analysis combines the disclosed financials with sector dynamics to infer strategic implications. Overall, Agilent’s QQ3 2025 results reinforce its position as a diversified, cash-generating provider in the laboratory instrumentation space, with meaningful growth drivers in high-margin service and consumables and a multi-segment portfolio that supports resilience against cyclicality.